Director of Product Management, Sequencing

NanoString Technologies
Job Location
San Francisco, CA 94301

NanoString provides competitive benefits including but not limited to: Stock Options, ESPP, Matching 401K, Annual Bonus, M/D/V, Parental Leave, Paid Holidays, PTO, etc.

Job Description

Nanostring is seeking an experienced, Director of Product Management to establish and drive all aspects of its Next Generation Sequencing (NGS) business.  This is an opportunity to work in a dynamic and entrepreneurial environment while playing a leading role in developing a new sequencing platform and driving NanoString's entry into the NGS market.  The new platform will utilize NanoString's proprietary enzyme free, amplification free, hybridization-based single molecule sequencing chemistry called Hyb & SeqTM.  This chemistry combines fluorescent molecular barcodes with multi-pass low error rate reads to generate highly accurate data.  The role will require a high degree of business acumen balanced by technical expertise and leadership skills.  The successful candidate will demonstrate a thorough understanding of the market for both current and future NGS technologies.

Location: We are opening a new satellite office in the San Francisco area. We are expecting the office to be between South San Francisco and Palo Alto. This position will require regular visits to our HQ in Seattle. 


  • Business & Program Strategy: Take ownership of the NGS program including product strategy, conceptualization and commercialization plans.  Work closely with the CEO and executive team in order to insure the program executes to the business plan and aligns with the overall corporate strategy.
  • Product Strategy:  Take overall ownership of the product definition by providing market inputs to the development and cross-organizational teams. Initiate and manage key opinion leader relationships to support both the development and the commercialization of the product  
  • Marketing & Commercialization Strategy: Define the strategy, lead and execute the overall marketing and commercialization plan including the active involvement of key opinion leaders, the execution of beta and early access programs, the global channel strategy, campaigns, collateral and sales tools.  
  • At least Ten (10) years' experience in marketing, product management or other commercial role.
  • Experience leading teams, collaborating across the company enterprise and building effective business relationships
  • Experience taking next generation sequencing products from concept to launch.
  • Advanced degree in Life Sciences (MSc or PhD) required.  MBA Preferred.
  • Demonstrated experience in working and communicating directly with the CEO, the executive leadership team and key opinion leaders
  • Action and results oriented. Takes ownership of important issues. Demonstrates persistence in the face of obstacles.
  • Is curious and inquisitive. Achieves innovative solutions. Approaches problems from a customer perspective. Develops solutions with sustainable and scalable results.
  • Self-motivated, highly organized, and meticulous in details.
  • Exceptional analytical skills and proficiency with MS Excel.
  • Must be able to work independently, manage multiple projects, communicate proactively, and prioritize daily tasks.
About Our Organization

ORLANDO, Fla., Feb. 11, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today presented the first proof-of-concept data for its novel massively parallel single molecule sequencing chemistry, Hyb & SeqTM, at the Advances in Genome Biology and Technology (AGBT) Meeting being held in Orlando, Florida. Hyb & Seq chemistry is based on NanoString's proprietary optical barcoding technology with several unique features giving it the potential to provide highly accurate data with a simple, efficient workflow. The new chemistry was presented in a poster titled, "Enzyme-free, Amplification-free, Hybridization-based Single Molecule Sequencing (Hyb & SeqTM)," the abstract for which is provided below.

The Hyb & Seq chemistry is designed to enable a workflow that is simpler and faster than current sequencing methods due to the absence of library preparation, enzymes and amplification, while providing both short and long read capability. In proof-of-concept experiments, Hyb & Seq chemistry demonstrated a low intrinsic error rate, and the ability to provide high consensus accuracy at low coverage by non-destructively sequencing the same native DNA multiple times. Chad Nusbaum, Ph.D., a member of NanoString's Sequencing Advisory Board, commented, "I'm very excited about the potential of the Hyb & Seq chemistry. The combination of simple workflow and low error rate make it a promising basis for the development of a targeted sequencing system that would be well positioned for clinical applications."

As described in the poster, Hyb & Seq works through four basic steps. First, native DNA molecules from regions of interest are captured on a flow cell. Second, the captured DNA is washed with a mixture of probes containing fluorescent optical barcodes that hybridize to matched regions along the target DNA molecule. Third, the optical barcodes of the hybridized probes are read to identify both the base and position identities. Finally, the probes are washed away and the cycle is then repeated until the targeted regions have been read sufficiently to assemble the DNA sequence.

The proof-of-concept data was achieved using a prototype sequencer based on a modified nCounter SPRINTTM Profiler instrument and mixtures of synthetic DNA targets, including the BRAF V600E model system. The raw single pass error rate was measured at approximately 2% for a single target and between 2% and 4% for mixtures of ten targets. Joe Beechem, Ph.D., Senior Vice President of R&D forNanoString, commented, "Hyb & Seq is a natural extension of the company's optical barcoding technology, potentially providing another important dimension to our 3D BiologyTM applications. While potential commercialization of the chemistry is still several years away, we will continue to focus on development of the chemistry, and expect to present further data later this year."

Presentation Abstract

Hyb & SeqTM is an enzyme-free, amplification-free, single molecule sequencing chemistry using cyclic nucleic acid hybridization of fluorescent molecular barcoded n-mers. Targets are sequenced using barcodes with the structure:(nnb1b2b3b4b5b6nn—linker—r1r2r3r4r5r6), where: n = mixture of all 4 bases, b1 through b6 are the 6 contiguous bases that form the complement to the target DNA/RNA to be sequenced, and r1 through r6 is a sub-diffraction-limited cyclically-read optical barcode that encodes the identity of the six-bases hybridized to that target via 4-color fluorescence (~25 fluorophores per "r").

Genomic DNA or RNA is first "gapped" to generate a single-stranded region and captured onto a flow-cell. Optical barcodes are hybridized to these single-molecule targets, and bases at each hybridized target are read through a series of 6 "fast-exchange" hybridizations to the reporter (r)-regions. Each cycle yields a 6-base read. The hybridized probes are eluted, and the cycle is repeated until all regions have sufficient coverage.

Proof-of-concept was achieved using a prototype sequencer based on a modified nCounter Sprint Profiler instrument and BRAF V600E model system. Fast reporter readout-cycling was confirmed ( < 10 seconds). The raw single-pass error rate averaged 2.1% (min = 0.66%, max = 3.72%) and did not reveal any systematic bias. Based on this data, less than 5x coverage from a single molecule would be required to reach a consensus sequence accuracy of 99.99% (Q40).

Hyb & Seq has many potential advantages over other sequencing chemistries. Read lengths can be as long as the gapped single-stranded regions. Sequencing error is independent of read length. No covalent bonds are formed, making each cycle non-destructive and allowing multiple reads on the same native single molecule, drastically reducing error rates. The workflow does not require enzymes, amplification, or libraries, opening the possibility of a sample-to-answer sequencing instrument appropriate for clinical use.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

Patricia Fara writes about childcare funding, and women in science and science history at NPR.

National Institute of Environmental Health Sciences researchers have visualized the career paths of former postdocs.

A new survey from the Pew Research Center finds that half of women working in STEM have experienced gender discrimination at work.

A proposal to tax students' tuition waivers no longer appears in the US tax bill, Vox reports.